Fenofibrate: An Underused Drug in Treatment of ARDS in COVID-19

Authors
Dr Sidhartha Sankar Bhuyan¹, Dr Rakesh Mohanty², Dr Swayamprava Sasmal³
¹Junior Resident, Department of Internal Medicine, VIMSAR, Burla
²Junior Resident, Department of Internal Medicine, VIMSAR, Burla
³Junior Resident, Department of Pathology, MKCG MCH, Berhampur

Abstract
Most of the deaths caused by the severe acute respiratory syndrome corona virus 2 (sars-cov-2) is attributable to the high incidence of Acute respiratory distress syndrome (ARDS). The mechanism of ARDS has been debatable, with recent researches postulating an inflammatory induced pro-thrombotic state associated with abnormal lipid generation. Fenofibrate, a widely available low-cost generic drug approved by the FDA, may be beneficial in covid-19 owing to its lipid lowering as well as immunomodulatory effects.

Keywords: Covid-19, ARDS, Fenofibrate.

Introduction
The COVID-19 pandemic has affected millions of people worldwide and has caused over one million deaths. Although most of the patients have a favourable prognosis, few develop pneumonia and severe hypoxaemia eventually leading to ARDS and death.

Pathology of ARDS in COVID-19
ARDS is a form of lung injury that occurs in response to various predisposing factors. It is characterised by inflammation, increased pulmonary vascular permeability and loss of aerated lung tissue. The diagnosis of ARDS is based upon severe hypoxaemia bilateral radiographic opacities occurring within 7 days of exposure to known predisposing factors¹. Central to the pathophysiology of ARDS is the presence of fibrin rich exudates (hyaline membranes) due to activation of coagulation and inhibition of fibrinolysis². The COVID-19 virus stimulates the induction of T-cells over-activation leading to excessive release of inflammatory mediators like tumour necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), IL-8, IL-10 and vascular endothelial growth factor³. All these factors contribute to upregulation of procoagulant activities in the alveolar compartment leading to intra-alveolar fibrin deposition and development of ARDS⁴. Levels of D-dimer, a by-product of clot degradation, are significantly increased in patients with ARDS⁵. Recent studies indicate widespread pulmonary vascular thrombosis is a consistent feature of ARDS⁶. Increased serum levels of D-dimer⁷ and pulmonary vascular endothelialitis, thrombosis and angiogenesis⁸ have been observed in patients with COVID-19.

Role of fenofibrate
Fenofibrate⁹ is a synthetic phenoxy-isobutyric acid derivative and prodrug with anti-hyperlipidemic activity. Fenofibrate is hydrolysed
in vivo to its active metabolite Fenofibric acid that binds to and activates peroxisome proliferator activated receptor alpha (PPAR-alpha), resulting in the activation of lipoprotein lipase and reduction of the production of apoprotein C-III, an inhibitor of lipoprotein lipase activity. Increased lipolysis and a fall in plasma triglycerides lead to increased catabolism of low density lipoprotein (LDL). Activation of PPAR-alpha increases synthesis of apoproteins AI and HDL. Overall Fenofibrate reduces total cholesterol, LDL cholesterol, total TG, and TG rich VLDL, while increasing HDL Cholesterol.

Apart from this TG lowering action, Fenofibrate has pleiotropic effects such as anti-inflammatory, anti-oxidant and anti-angiogenesis activities. It can downregulate levels of nuclear factor-kappa beta (NF-KB), TNF-alpha, IL-6, vascular adhesion molecules, cyclooxygenase-2, matrix metalloproteinase, vascular endothelial growth factor-1 signalling and oxidative stress. All these effects of Fenofibrate may help to reduce the harmful inflammatory responses in the body. Besides that, as Fenofibrate is effective in lowering fibrinogen, it may serve as a highly valuable therapy for patients with severe COVID-19, especially those suffering from cytokine storm.

One drawback for Fenofibrate is its ability to upregulate the expression of angiotensin converting enzyme-2 (ACE2) which increases the risk of viral entry to the cells. This problem can be counteracted by addition of chloroquine or hydroxy-chloroquine, as these drugs inhibit the glycosylation of ACE2 and thereby hinders the binding of viral spike protein to ACE2 and prevent viral entry.

**Conclusion**

Fenofibrate is a low cost widely available generic drug which seems to have beneficial effects in treatment of COVID-19, particularly its ability to downregulate ARDS. So use of this drug may be extremely helpful at times when the entire scientific community is putting tremendous effort to find ways to alleviate this global Pandemic.

**References**

4. Ji HL Zhao R Matalon S Matthay MA, Elevated plasminogen as a Common Risk Factor for COVID-19 Susceptibility. Physiol Rev. 2020; 100: 1065-1075


